Our ongoing series of Drug Pipeline Insights can be accessed from this page. Peruse the links below for the latest commentary, trends, predictions and expert analysis on what's coming to market!
- 2026 Q2 Update: The the arrival of generic semaglutide and major market trends that will influence future competition, reimbursement and pharmacy practice.
- 2026 Q1 Update: A wave of high-value generic launches—including major diabetes and oncology drugs—signals one of the most commercially impactful years for pharmacy in over a decade
- 2026 Q2 Update: Latest biosimilar approvals, evolving market dynamics and important regulatory changes that could accelerate future biosimilar competition and expand treatment options for Canadian
- 2026 Q1 Update: An increasingly crowded biosimilars market—led by blockbuster biologics like aflibercept and denosumab—creates new competitive dynamics and savings opportunities pharmacies can’t afford to miss.
- 2026 Q2 Update: Latest wave of innovative therapies entering the Canadian market—from breakthrough treatments for rare diseases and Alzheimer's disease to new vaccines and specialty medicines
- 2026 Q1 Update: From rare disease breakthroughs to cutting-edge oncology therapies, the latest round of new drug approvals and submissions is set to reshape future pharmacy care.
Our Q1 Spotlight focuses on Semaglutide and explores the explosive growth of GLP-1 therapies like Ozempic, Wegovy, and Rybelsus, the anticipated entry of generics in 2026, and what it all means for pharmacy revenues, pricing, and patient access.
Health Canada Approvals
Our curated weekly snapshot of new and notable drug approvals across a variety of drug classes to keep pharmacy operators in the know.
